About

Non-small-cell lung cancer is the most common form of lung cancer, accounting for about 85% of cases, and it tends to respond poorly to chemotherapy, so surgery is usually the preferred treatment when the disease is caught early. Neladalkib is an oral medicine that selectively blocks ALK, a protein that drives cancer growth in some lung tumors, and it is designed to reach the brain as well. Because ALK-positive tumors depend on that protein to grow, blocking it may slow or stop the cancer—including cancer that has spread to the brain—though the benefit is still being confirmed.